Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04153539
Other study ID # FDUEH-6
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 9, 2019
Est. completion date December 31, 2022

Study information

Verified date March 2022
Source Fudan University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to assess the effects of acute exposure to traffic-related air pollution and the underlying mechanisms.


Description:

The investigators will conduct a randomized, crossover trial among 72 healthy young adults in Shanghai, China. The eligible participants will be randomly divided into 2 groups (36 volunteers per group). During the first stage, participants will be requested to take one walking task (from 13:00 to 17:30). The exposed group will walk along a busy road and be exposed to traffic-related air pollution, while the control group will walk in a traffic-free park. During the first 3 hours, all participants will rest for 30 minutes after each 15-minute walking. From 16:00, participants will stop walking and rest for 1.5 hours. Then both groups will enter a 2-week washout period. In the second stage, there will also be one walking task (from 13:00 to 17:30). The two groups will exchange their walking sites and repeat the previous trial. Physical examinations will be performed both before and after each walking task. Besides, we will ask volunteers to stay in school during the two days before walking. Health examinations include symptoms questionnaires, blood pressure tests, Holter monitoring, and spirometry. We plan to collect blood, urine, oropharyngeal swabs, and exhaled breath condensate before exposure, about one hour after exposure, and next morning.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 69
Est. completion date December 31, 2022
Est. primary completion date December 8, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria: - Living in Shanghai during the study period; - Body mass index > 18.5 and = 28; - Non-smoking, no history of alcohol or drug abuse; - Completing the walking task we required. Exclusion Criteria: - Current or ever smokers; - Subjects with allergic disease, such as allergic rhinitis, allergic asthma, and atopy; - Subjects with cardiovascular disease, such as congenital heart disease, pulmonary heart disease, and hypertension; - Subjects with respiratory disease, such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease; - Subjects wih chronic disease, such as diabetes, chronic hepatitis, and kidney disease; - Subjects with a history of major surgery; - Abnormal spirometry (FEV1 and FVC = 75% of predicted and FEV1/FVC = 0.65); - Medication use or dietary supplements intake in recent two months;

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Walking along a busy road
The intervention group will walk along a busy road and be exposed to traffic-related air pollution for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
Walking in a traffic-free park
The control group will walk in a traffic-free park for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.

Locations

Country Name City State
China Department of Environmental Health, School of Public Health, Fudan University Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Differences in DNA methylation levels detected in whole-blood between the two exposures Genome-wide DNA methylation in whole-blood were detected using Illumina 850K Beadchip. The study is to identify differential CpG loci after TRAP exposure 1 hour after the end of the exposure session
Other Differences in exosome RNA expression levels detected in plasma transcriptomics between the two exposures Illumina-based transcriptomics is non-targeted. The study is to find the differentially expressed exosome RNA in plasma after TRAP exposure 1 hour after the end of the exposure session
Other Differences in exosome miRNA expression levels detected in plasma transcriptomics between the two exposures Illumina-based transcriptomics is non-targeted. The study is to find the differentially expressed exosome miRNA in plasma after TRAP exposure 1 hour after the end of the exposure session
Other Differences in protein levels detected in plasma proteomics between the two exposures Mass spectrometry-based plasma proteomics is non-targeted. The study is to find the differentially expressed proteins in plasma after TRAP exposure 1 hour after the end of the exposure session
Other Differences in metabolic profiling detected in serum mass spectrometry-based non-targeted metabolomics between the two exposures The study is to explore the differential metabolic profiling in serum after TRAP exposure. 1 hour after the end of the exposure session
Other Differences in metabolic profiling detected in urine mass spectrometry-based non-targeted metabolomics between the two exposures The study is to explore the differential metabolic profiling in urine after TRAP exposure. 1 hour after the end of the exposure session
Other Differences in lipids levels detected in serum lipidomics between the two exposures Mass spectrometry-based serum lipids is non-targeted. The study is to find the differential lipids in serum between the road scenario and the park scenario 1 hour after the end of the exposure session
Other Differences in protein levels detected in targeted serum proteomic chip between the two exposures Targeted serum proteomic chip was conducted using the RayBio Biotin Label-based Human Antibody Array, which covers a total of 507 human proteins, including cytokines, inflammatory proteins, growth factors, cell adhesion molecules, soluble receptors and chemokines, and proteins related to angiogenesis and atherosclerosis. The study is to find the differential proteins in serum between the road scenario and the park scenario 1 hour after the end of the exposure session
Other Differences in metabolic profiling detected in airway mass spectrometry-based non-targeted metabolomics between the two exposures The study is to explore the differential metabolic profiling in exhaled breath condensate after TRAP exposure. 1 hour after the end of the exposure session
Other Change in CRP concentrations Change in the serum concentrations of C-reactive protein 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Change in ITAC concentrations Change in the serum concentrations of Interferon-induced T-cell alpha chemoattractant 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Change in GM-CSF concentrations Change in the serum concentrations of Granulocyte-macrophage colony-stimulating factor 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Change in IFN-gamma concentrations Change in the serum concentrations of Interferon-gamma 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Change in IL-10 concentrations Change in the serum concentrations of Interlukin-10 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Change in IL-17A concentrations Change in the serum concentrations of Interleukin-17A 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Change in IL-1 beta concentrations Change in the serum concentrations of Interlukin-1 beta 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Change in IL-23 concentrations Change in the serum concentrations of Interleukin-23 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Change in IL-6 concentrations Change in the serum concentrations of Interleukin-6 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Change in IL-8 concentrations Change in the serum concentrations of Interleukin-8 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Change in TNF alpha concentrations Change in the serum concentrations of Tumor necrosis factor-a 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Change in MDA concentrations Change in the serum concentrations of Malondialdehyde 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Change in 8-OH-DG concentrations Change in the urine concentrations of 8-hydroxy-2'-deoxyguanosine 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Change in ACE concentrations Change in the serum concentrations of Angiotensin converting enzymes 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session
Other Change in Angiotensin II concentrations Change in the serum concentrations of Angiotensin II 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session
Other Change in ALD concentrations Change in the urine concentrations of Aldosterone 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session
Other Change in TF concentrations Change in the serum concentrations of Tissue factor 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session
Other Change in Fibrinogen concentrations Change in the serum concentrations of Fibrinogen 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session
Other Change in PAI-1 concentrations Change in the serum concentrations of Plasminogen Activator inhibitor-1 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session
Other Change in vWF concentrations Change in the serum concentrations of von Willebrand factor 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session
Other Change in CRF concentrations Change in the serum concentrations of Corticotropin-Releasing Factor 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Change in ACTH concentrations Change in the serum concentrations of Adrenocorticotropic hormone 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Change in Cortisol concentrations Change in the serum concentrations of Cortisol 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Change in Cholesterol concentrations Change in the serum concentrations of Cholesterol 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Change in TAG concentrations Change in the serum concentrations of Triglyceride 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Change in LDL-C concentrations Change in the serum concentrations of Low-density lipoprotein cholesterol 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Change in Glucose concentrations Change in the serum concentrations of Glucose 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Change in Insulin concentrations Change in the serum concentrations of Insulin 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session, and 7:00 AM in the next morning
Other Changes in SP-D concentrations Change in the serum concentrations of surfactant proteins D 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session
Other Changes in Ezrin concentrations Change in the exhaled breath condensate concentrations of Ezrin 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session
Other Changes in 8-isoprostane concentrations between the two exposures Change in the exhaled breath condensate concentrations of 8-isoprostane 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session
Other Changes in TNF-a concentrations Change in the exhaled breath condensate concentrations of tumor necrosis factor-a 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session
Other Changes of the scores of respiratory symptoms questionnaires Changes of scores of respiratory symptoms questionnaires both the total and each symptom specified 7:00 AM on the day of the walking session, 1 hour after the end of the exposure session
Primary Changes in FEV1 We plan to measure changes in forced expiratory volume in 1 second. FEV1 will be examined before exposure, half an hour after exposure and 12 hours after exposure.
Primary Blood Pressure We plan to measure systolic blood pressure (SBP) and diastolic blood pressure (DBP). Blood pressure will be measured for 24 hours from 8:00 am on the morning of intervention to 8:00 am on the next morning.
Primary Heart Rate Variability Parameters We plan to measure heart rate variability (HRV) parameters. Volunteers will be asked to wear electrographic Holter monitors for 24 hours from 8:00 am on the morning of intervention to 8:00 am on the next morning.
Secondary Changes of FVC Changes of forced vital capacity 7:00 AM on the day of the walking session, half an hour after exposure and 12 hours after exposure (next morning)
Secondary Changes of FEV1/FVC Changes of the ratio of forced expired volume in 1 second (FEV1) to forced vital capacity (FVC) 7:00 AM on the day of the walking session, half an hour after exposure and 12 hours after exposure (next morning)
Secondary Changes of MMEF Changes of maximal mid-expiratory flow 7:00 AM on the day of the walking session, half an hour after exposure and 12 hours after exposure (next morning)
See also
  Status Clinical Trial Phase
Completed NCT03697499 - Effects of Fish Oil in Alleviating Health Hazards Associated With Ozone Exposure N/A
Completed NCT04579497 - Temperature-dependent Changes in Cardiovascular Parameters During Warm Water Footbaths in Healthy Women N/A
Active, not recruiting NCT05575752 - Acute Health Effects of High Temperature Exposure N/A
Completed NCT02977390 - Passive Leg Raise Induced Stroke Volume Changes in Elderly Prior to Elective Surgery Measured by LiDCOplusTM N/A
Not yet recruiting NCT06076629 - Acute Health Effects of Low Temperature Exposure N/A
Completed NCT05866848 - Effects of Caffeine on Cerebral Blood Flow N/A
Completed NCT05289817 - Effects of Transcutaneous Electrical Stimulation on the Autonomous Nerve System in Healthy Young People N/A
Completed NCT04209738 - Changes in Cardiovascular and Sleep Quality Parameters Under Eurythmy Therapy and Tai Chi in Comparison to Standard Care - A Substudy of the ENTAiER Trial
Active, not recruiting NCT05727332 - Vascular Adaptations to Single-Sprint Training N/A
Completed NCT02979327 - Cardiovascular Effects of Adderall in Healthy Adults. Early Phase 1
Completed NCT01940822 - Cardiovascular Effects of Energy Drinks in Healthy Adults N/A
Completed NCT03395977 - Uric Acid Effects on Endothelium and Oxydative Stress N/A
Completed NCT03810118 - Fluid Challenge Infusion and Response N/A